U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335497) titled 'CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors' on Jan. 08.
Brief Summary: The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Locally Advanced / Metastatic Solid Tumors
Intervention:
DRUG: CR-001
Intravenous Infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Crescent Biopharma, Inc.
Published by HT Digi...